A paradigm shift from the conventional cell culture techniques to 3D cell culture is predicted to bring humongous growth for the 3D cell culture market across the forecast period of 2017-2025. From the validation of new targets and disease modeling to screening for safety and efficacy, 3D cell cultures bring the tremendous potential for the development of new drugs. They offer cutting-edge tools that assist in exploring the major factors of a particular disease.
In addition, 3D cell culture market gains mainly from the cancer segment as 3D models can mimic the interplay between the host environment and tumor for analyzing the efficacy of drug candidates in cancer patients. Greater biological relevance as compared to 2D monolayers is a prime advantage for an increase in the growth rate of the 3D cell culture market. In addition, 3D cell culture systems allow better cell interactions than done in 2D cell culture systems. Advances in microfabrication techniques, tissue engineering, and cell biology are supporting the development of varied 3D cell culture technologies.
The stem cell segment is anticipated to observe prominent growth during the forecast period of 2017-2025. Increased differentiation potential of stem cells under 3D cell culture may benefit the 3D cell culture market to a great extent. Pharmaceuticals and biotechnology sector expects to bring a larger revenue share throughout the forecast period owing to increasing demand for 3D cell culture systems for toxicity screening, drug discovery, and regenerative medicine.
Mergers, Acquisitions, and Partnerships Fuelling Market Growth
The advantages associated with the 3D cell culture system are resulting in frequent partnerships and acquisitions. Key players are involved in such activities to increase their footprint in the 3D cell culture market as well as speed up the process of new developments. zPREDICTA, a San Jose-based company, recently partnered with Labcorp for extending its customer base. zPREDICTAis a specialist in the development of tumor-specific 3D cell culture models and Labcorp is involved in operating a nationwide network of clinical laboratories. In another development, Nichirei Biosciences Inc. partnered with UPM Biomedicals to offer hydrogels that mimic the extracellular matrix (ECM) to encourage cell growth and differentiation. This development will help in bridging the gap between in vitro and in vivo studies by enabling 3D cell organoids for use in regenerative and personalized medicine. Similarly, Greiner Bio-One acquired Nano 3D Biosciences’ 3D cell culture technology.
New Insights and Developments Accelerating the Growth Rate
Disease modeling is an essential component for the discovery of a drug-related to a specific disease or disorder. With the help of 3D bioprinting and tissue engineering techniques, it is possible to unravel drug discovery. Therefore, this aspect can propel the growth rate of the 3D cell culture market.
For instance, the COVID-19 outbreak is motivating key players in the 3D cell culture market to come up with new developments and technologies for novel treatments that can tackle the deadly disease. For instance, the SARS-CoV-2 pandemic prompted Inventialifescience, an Australia based startup, to create 3D lung microtissues for drug testing. This is being developed through the company’s bioprinting platform, Rastrum, which is being used to print human cells with cancer drug testing at a rapid rate.
To Get an Exhaustive Overview about the Competition in 3D Cell Culture Market, Request for a Report Brochure at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35834
From the regional perspective, developed regions like North America and Europe are predicted to show an increasing growth curve across the forecast period, with increasing cancer cases and rising investment in research and development activities being the prime factors for growth. Asia Pacific also expects steady growth due to considerable demand for 3D cell culture systems in the developing regions.
Key players involved in the 3D cell culture market are ReproCELl, Thermo Fisher Scientific Inc., Global Cell Solutions, Hamilton Company, Kuraray Co. Ltd., and Merck.